STABLECOIN DEVELOPMENT CORPORATION Forms 3, 4 and 5: Warrants
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 44 rows, 44 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-06-15: Reporting owner Kazley Michael John; Form 4; Security Pre-Funded Warrants (Right to Buy); Transaction X Exercise of in-the-money or at-the-money derivative security.
- 2026-06-15: Reporting owner Framework Ventures Management LLC | Framework Ventures IV GP LLC | Anderson Michael Ernest | Spencer Vance | Framework Ventures IV L.P.; Form 4; Security Pre-Funded Warrants (Right to Buy); Transaction X Exercise of in-the-money or at-the-money derivative security.
- 2026-06-15: Reporting owner R01 Capital Manager LLC | R01 Capital LLC | Kazley Michael John | R01 Fund LP; Form 4; Security Pre-Funded Warrants (Right to Buy); Transaction X Exercise of in-the-money or at-the-money derivative security.
- 2026-01-16: Reporting owner Anderson Michael Ernest | Framework Ventures IV GP LLC | Framework Ventures IV L.P. | Spencer Vance | Framework Ventures Management LLC; Form 4; Security Pre-Funded Warrants (Right to Buy); Transaction P Open market or private purchase of non-derivative or derivative security.
SDEV insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-15 | Kazley Michael John Director, Officer (Chief Executive Officer), 10% Owner | 4 | Pre-Funded Warrants (Right to Buy) Derivative · Indirect · By R01 Entities | X Exercise of in-the-money or at-the-money derivative security | +11,332,020 0 owned after | $0.00 | $1.08 | 2026-06-17 |
| 2026-06-15 | Framework Ventures Management LLC | Framework Ventures IV GP LLC | Anderson Michael Ernest | Spencer Vance | Framework Ventures IV L.P. 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Pre-Funded Warrants (Right to Buy) Derivative · Direct | X Exercise of in-the-money or at-the-money derivative security | +11,332,020 0 owned after | $0.00 | $1.08 | 2026-06-17 |
| 2026-06-15 | R01 Capital Manager LLC | R01 Capital LLC | Kazley Michael John | R01 Fund LP 10% Owner | 10% Owner | 10% Owner | Director, Officer (Chief Executive Officer), 10% Owner | 4 | Pre-Funded Warrants (Right to Buy) Derivative · Direct | X Exercise of in-the-money or at-the-money derivative security | +11,332,020 0 owned after | $0.00 | $1.08 | 2026-06-17 |
| 2026-01-16 | Anderson Michael Ernest | Framework Ventures IV GP LLC | Framework Ventures IV L.P. | Spencer Vance | Framework Ventures Management LLC 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Pre-Funded Warrants (Right to Buy) Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +50,109,253 50,109,253 owned after | $0.85 | $73.85 | 2026-05-19 |
| 2026-01-16 | R01 Capital Manager LLC | R01 Capital LLC | R01 Fund LP | Kazley Michael John 10% Owner | 10% Owner | Director, Officer (Chief Executive Officer), 10% Owner | 10% Owner | 4 | Pre-Funded Warrants (Right to Buy) Derivative · Indirect · By R01 Entities | P Open market or private purchase of non-derivative or derivative security | +53,679,974 53,679,974 owned after | $0.85 | $73.85 | 2026-05-19 |
| 2026-01-16 | Kazley Michael John Director, Officer (Chief Executive Officer), 10% Owner | 4 | Pre-Funded Warrants (Right to Buy) Derivative · Indirect · By R01 Entities | P Open market or private purchase of non-derivative or derivative security | +53,679,974 53,679,974 owned after | $0.85 | $73.85 | 2026-05-19 |
| 2025-10-16 | Kazley Michael John Director, Officer (Chief Executive Officer), 10% Owner | 4/A | Pre-Funded Warrants (Right to Buy) Derivative · Indirect · By R01 Entities | P Open market or private purchase of non-derivative or derivative security | +11,332,020 11,332,020 owned after | $0.01 exercise price | $5.70 | 2026-04-30 |
| 2025-10-16 | Framework Ventures IV L.P. | Framework Ventures IV GP LLC | Spencer Vance | Framework Ventures Management LLC | Anderson Michael Ernest 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4/A | Pre-Funded Warrants (Right to Buy) Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +11,332,020 11,332,020 owned after | $0.01 exercise price | $5.70 | 2026-04-30 |
| 2025-10-16 | R01 Fund LP | R01 Capital Manager LLC | Kazley Michael John | R01 Capital LLC Director, Officer (Chief Executive Officer), 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4/A | Pre-Funded Warrants (Right to Buy) Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +11,332,020 11,332,020 owned after | $0.01 exercise price | $5.70 | 2026-04-30 |
| 2025-10-16 | Framework Ventures IV GP LLC | Framework Ventures Management LLC | Spencer Vance | Framework Ventures IV L.P. | Anderson Michael Ernest 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Pre-Funded Warrants (Right to Buy) Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +2,702,703 2,702,703 owned after | $0.01 exercise price | $5.70 | 2025-11-03 |
| 2025-10-16 | Kazley Michael John | R01 Capital Manager LLC | R01 Fund LP | R01 Capital LLC 10% Owner | 10% Owner | Director, Officer (Chief Executive Officer), 10% Owner | 10% Owner | 4 | Pre-Funded Warrants (Right to Buy) Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +2,702,703 2,702,703 owned after | $0.01 exercise price | $5.70 | 2025-11-03 |
| 2025-10-16 | Kazley Michael John Director, Officer (Chief Executive Officer), 10% Owner | 4 | Pre-Funded Warrants (Right to Buy) Derivative · Indirect · By R01 Entities | P Open market or private purchase of non-derivative or derivative security | +2,702,703 2,702,703 owned after | $0.01 exercise price | $5.70 | 2025-11-03 |
| 2016-08-01 | Pioneer Pharma (Singapore) Pte. Ltd. 10% Owner | 4 | Warrant Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +654,451 1,490,202 owned after | $1.91 exercise price | $14,332.50 | 2016-08-02 |
| 2016-08-01 | SIECZKAREK MARK M Director, Officer (CEO) | 4 | Warrant Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +130,890 273,447 owned after | $1.91 exercise price | $14,332.50 | 2016-08-02 |
| 2016-05-09 | Fu Jian Ping 10% Owner | 4 | Warrant Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +968,587 1,095,572 owned after | $1.91 exercise price | $12,985.00 | 2016-05-16 |
| 2016-05-09 | Pioneer Pharma (Singapore) Pte. Ltd. 10% Owner | 4 | Warrant Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +654,451 835,751 owned after | $1.91 exercise price | $12,985.00 | 2016-05-13 |
| 2016-05-09 | SIECZKAREK MARK M Director | 4 | Warrant Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +130,890 142,557 owned after | $1.91 exercise price | $12,985.00 | 2016-05-13 |
| 2016-03-04 holding as of filing | Fu Jian Ping 10% Owner | 3 | Warrants (right to buy) Derivative · Direct | Holding | $19.50 exercise price | 2016-03-04 | ||
| 2015-03-03 | SIECZKAREK MARK M Director | 4 | Warrant Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +166,666 291,665 owned after | $0.60 | $90,343.75 | 2015-03-05 |
| 2015-03-03 | SIECZKAREK MARK M Director | 4 | Warrant Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +124,999 291,665 owned after | $0.65 | $90,343.75 | 2015-03-05 |
| 2015-03-03 | Najafi Ramin Director, Officer (Chief Executive Officer) | 4 | Warrant Derivative · Indirect · Ownership through the Najafi Family Trust | P Open market or private purchase of non-derivative or derivative security | +166,666 291,665 owned after | $0.60 | $90,343.75 | 2015-03-05 |
| 2015-03-03 | Najafi Ramin Director, Officer (Chief Executive Officer) | 4 | Warrant Derivative · Indirect · Ownership through the Najafi Family Trust | P Open market or private purchase of non-derivative or derivative security | +124,999 291,665 owned after | $0.65 | $90,343.75 | 2015-03-05 |
| 2015-03-03 | Pioneer Pharma (Singapore) Pte. Ltd. 10% Owner | 4 | Warrant Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +2,590,000 4,532,500 owned after | $0.60 | $90,343.75 | 2015-03-05 |
| 2015-03-03 | Pioneer Pharma (Singapore) Pte. Ltd. 10% Owner | 4 | Warrant Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +1,942,500 4,532,500 owned after | $0.65 | $90,343.75 | 2015-03-05 |
| 2013-12-02 | China Pioneer Pharma Holdings Ltd 10% Owner | 4 | Common Stock Purchase Warrant (Right to Buy) Derivative · Indirect · By Pioneer Pharma (Singapore)Pte. Ltd. | H Expiration (or cancellation) of long derivative position with value received | −800,000 0 owned after | $1.50 exercise price | $212,843.75 | 2013-12-04 |
| 2013-12-02 | China Pioneer Pharma Holdings Ltd 10% Owner | 4 | Common Stock Purchase Warrant (Right to Buy) Derivative · Indirect · By Pioneer Pharma (Singapore)Pte. Ltd. | H Expiration (or cancellation) of long derivative position with value received | −1,200,000 0 owned after | $1.50 exercise price | $212,843.75 | 2013-12-04 |
| 2013-12-02 | Pioneer Pharma (Singapore) Pte. Ltd. 10% Owner | 4 | Common Stock Purchase Warrant (Right to Buy) Derivative · Direct | H Expiration (or cancellation) of long derivative position with value received | −800,000 0 owned after | $1.50 exercise price | $212,843.75 | 2013-12-04 |
| 2013-12-02 | Pioneer Pharma (Singapore) Pte. Ltd. 10% Owner | 4 | Common Stock Purchase Warrant (Right to Buy) Derivative · Direct | H Expiration (or cancellation) of long derivative position with value received | −1,200,000 0 owned after | $1.50 exercise price | $212,843.75 | 2013-12-04 |
| 2013-12-02 | Pioneer Pharma (Hong Kong) Co Ltd 10% Owner | 4 | Common Stock Purchase Warrant (Right to Buy) Derivative · Indirect · By Pioneer Pharma (Singapore) Pte. Ltd. | H Expiration (or cancellation) of long derivative position with value received | −800,000 0 owned after | $1.50 exercise price | $212,843.75 | 2013-12-04 |
| 2013-12-02 | Pioneer Pharma (Hong Kong) Co Ltd 10% Owner | 4 | Common Stock Purchase Warrant (Right to Buy) Derivative · Indirect · By Pioneer Pharma (Singapore) Pte. Ltd. | H Expiration (or cancellation) of long derivative position with value received | −1,200,000 0 owned after | $1.50 exercise price | $212,843.75 | 2013-12-04 |
| 2013-12-02 holding as of filing | Pioneer Pharma (Hong Kong) Co Ltd 10% Owner | 3 | Common Stock Purchase Warrant (Right to Buy) Derivative · Indirect · By Pioneer Pharma (Singapore) Pte. Ltd. | Holding | $1.50 exercise price | 2013-12-02 | ||
| 2013-12-02 holding as of filing | Pioneer Pharma (Hong Kong) Co Ltd 10% Owner | 3 | Common Stock Purchase Warrant (Right to Buy) Derivative · Indirect · By Pioneer Pharma (Singapore) Pte. Ltd. | Holding | $1.50 exercise price | 2013-12-02 | ||
| 2013-12-02 holding as of filing | China Pioneer Pharma Holdings Ltd 10% Owner | 3 | Common Stock Purchase Warrant (Right to Buy) Derivative · Indirect · By Pioneer Pharma (Singapore) Pte. Ltd. | Holding | $1.50 exercise price | 2013-12-02 | ||
| 2013-12-02 holding as of filing | China Pioneer Pharma Holdings Ltd 10% Owner | 3 | Common Stock Purchase Warrant (Right to Buy) Derivative · Indirect · By Pioneer Pharma (Singapore) Pte. Ltd. | Holding | $1.50 exercise price | 2013-12-02 | ||
| 2013-01-02 holding as of filing | Li Xinzhou 10% Owner | 3 | Warrant Derivative · Indirect · The warrants are held by Pioneer Pharma (Singapore) Pte. Ltd., a 100% wholly owned subsidiary of Naq | Holding | $1.50 exercise price | 2013-01-02 | ||
| 2012-12-06 | Stroman David W. Officer (SVP, Ophthalmic Product Devt.) | 4 | Warrants to purchase Common Stock Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +7,500 7,500 owned after | $0.01 | $174,562.50 | 2012-12-10 |
| 2012-12-06 | PAULSON THOMAS J Officer (CFO) | 4 | warrant to purchase Common Stock Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +7,500 7,500 owned after | $0.01 | $174,562.50 | 2012-12-10 |
| 2012-12-06 | Najafi Ramin Director, Officer (Chief Executive Officer) | 4 | Warrants to Purchase Common Shares Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +15,000 15,000 owned after | $0.01 | $174,562.50 | 2012-12-10 |
| 2012-11-20 holding as of filing | NAQU AREA PIONEER PHARMA CO., LTD. 10% Owner | 3 | Warrant Derivative · Indirect · Pioneer Pharma (Singapore) Pte. Ltd. is a 100% wholly-owned subsidiary of Naqu Area Pioneer Pharma C | Holding | $1.50 exercise price | 2012-11-20 | ||
| 2012-11-05 holding as of filing | Pioneer Pharma (Singapore) Pte. Ltd. 10% Owner | 3 | Warrants Derivative · Direct | Holding | $1.50 exercise price | 2012-11-05 | ||
| 2012-10-31 | Li Xinzhou 10% Owner | 4 | Warrant Derivative · Indirect · The warrants are held by Pioneer Pharma (Singapore) Pte. Ltd., a 100% wholly owned subsidiary of Naq | P Open market or private purchase of non-derivative or derivative security | +1,200,000 2,000,000 owned after | $1.50 | $202,125.00 | 2013-01-02 |
| 2012-10-31 | NAQU AREA PIONEER PHARMA CO., LTD. 10% Owner | 4 | Warrant Derivative · Indirect · Pioneer Pharma (Singapore) Pte. Ltd. a 100% wholly-owned subsidiary of Naqu Area Pioneer Pharma Co. | P Open market or private purchase of non-derivative or derivative security | +1,200,000 2,000,000 owned after | $1.50 | $202,125.00 | 2012-11-20 |
| 2012-10-31 | Pioneer Pharma (Singapore) Pte. Ltd. 10% Owner | 4 | Warrant Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +1,200,000 2,000,000 owned after | $1.50 | $202,125.00 | 2012-11-05 |
| 2012-09-13 | Li Xinzhou 10% Owner | 4 | Warrant Derivative · Indirect · The warrants are held by Pioneer Pharma (Singapore) Pte. Ltd., a 100% wholly owned subsidiary of Naq | P Open market or private purchase of non-derivative or derivative security | +800,000 800,000 owned after | $1.50 | $228,156.25 | 2013-01-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FORUM MARKETS Inc (FRMM) | United States | $0.069B | -0.13 |
| ZeroStack Corp. (ZSTK) | $0.069B | -0.04 | |
| Exodus Movement, Inc. (EXOD) | United States | $0.073B | 2.92 |
| SkyAI, Inc. (SKYA) | United States | $0.081B | |
| Empery Digital Inc. (EMPD) | United States | $0.082B | -0.36 |
| BTCS Inc. (BTCS) | United States | $0.085B | -0.45 |
| Marygold Companies, Inc. (MGLD) | United States | $0.044B | -11.63 |
| AVAX ONE TECHNOLOGY LTD. (AVX) | $0.040B | -0.36 | |
| FG Nexus Inc. (FGNX) | United States | $0.039B | -429.84 |
| Big Digital Energy, Inc. (BGDE) | $0.035B |